EGFR and cancer: In order to overcome this resistance, a therapeutic armamentarium consisting of ICIs and anti-cancer agents with immunomodulatory effects (e.g., anti-VEGFR or anti-EGFR) has been proposed to enhance the immunogenic profile of these lesions and make checkpoint blockade more effective [45,46].